LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Начало・Списък с акции・Cytokinetics Inc

Cytokinetics Inc

Затворен

СекторЗдравеопазване

74.53 -2.89

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

74.04

Максимум

78.45

Ключови измерители
By Trading Economics
Приходи	123M -183M
Продажби	16M 18M
Марж на печалбата	-1,030.87
Служители	673
EBITDA	97M -180M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+29.87% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-140M 8.2B
Предишно отваряне	77.42
Предишно затваряне	74.53

Настроения в новините

By Acuity

40%

60%

134 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

32.3 / 40.43 Подкрепа & съпротива

Cytokinetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.05.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on AI Enthusiasm -- Market Talk

11.05.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Rises on Possible Position Adjustments -- Market Talk

11.05.2026 г., 22:37 ч. UTC

Пазарно говорене

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11.05.2026 г., 22:32 ч. UTC

Печалби

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11.05.2026 г., 22:02 ч. UTC

Пазарно говорене

Значими събития в новините

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11.05.2026 г., 21:49 ч. UTC

Печалби

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11.05.2026 г., 21:42 ч. UTC

Пазарно говорене

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11.05.2026 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

CSG Systems Sale to NEC Gets CFIUS Clearance

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv 1Q Loss/Shr $2.35 >OVV

11.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

11.05.2026 г., 20:44 ч. UTC

Печалби

Steris: Board Approves New $1B Shr Repurchase Program >STE

11.05.2026 г., 20:43 ч. UTC

Печалби

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Rev $136.4M >CLSK

11.05.2026 г., 20:30 ч. UTC

Печалби

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Cont Ops EPS $2.24 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Rev $1.6B >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Adj EPS $2.83 >STE

11.05.2026 г., 20:22 ч. UTC

Горещи акции

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11.05.2026 г., 19:37 ч. UTC

Печалби

More Bad News at KKR's Private Credit Fund -- Barrons.com

11.05.2026 г., 19:32 ч. UTC

Пазарно говорене

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cytokinetics Inc Прогноза

Ценова цел

By TipRanks

29.87% нагоре

12-месечна прогноза

Среден 99.88 USD 29.87%

Висок 140 USD

Нисък 67 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Cytokinetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

Купи

Задържане

Продай

Според 19 анализатори, дали борсови рейтинги на Cytokinetics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

32.3 / 40.43Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

134 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.